

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

The effect of neurofeedback with pharmacotherapy on cognitive ability and executive function in patients with obsessive - compulsive disorder

Protocol summary

Summary

(1) Main aim: The effect of neurofeedback with pharmacotherapy on cognitive ability and executive function in patients with obsessive - compulsive disorder, Goals: A- Comparison between the efficacy of Neurofeedback and Pharmacotherapy group, and placebo Neurofeedback and Pharmacotherapy group, and Pharmacotherapy group on cognitive abilities and executive functions in patients with obsessive-compulsive disorder. (2) Design: This study is a randomized single blind clinical controlled trial. (3) Setting and conduct: Study population consisted of patients with obsessive-compulsive disorder are referred to hospital in Hamadan farshchian that 45 person divided in 3 groups included Neurofeedback with Pharmacotherapy, placebo Neurofeedback and Pharmacotherapy, Pharmacotherapy alone will be randomly selected. Inclusion criteria: Diagnosis of obsessive-compulsive disorder based on the psychiatrist's interview According to DSM-5 criteria, receiving sertraline, Be at least 18 and up to 60 years, A minimum score of 16 on the Yale Brown Obsessive Compulsive Scale. Exclusion criteria: The people with acute and serious other mental disorders, the types of dementia and cognitive disabilities. Intervention and time: Group 1- In this group patient will receive Neurofeedback 2 times per week for 10 weeks and they also will receive sertraline 20-40 mg for 16 weeks. Group 2- placebo Neurofeedback 2 times per week for 10 weeks and they also will receive sertraline 20-40 mg for 16 weeks. Group 3- Receiving sertraline 10 mg for 16 weeks. All patients before and after the treatments will assess by Yale Brown Obsessive Compulsive Scale, CGI scale, Wisconsin, Stroop and Pasat tests. Outcome variables: Obsessive-compulsive disorders, cognitive abilities and executive functions.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2015030321313N1**

Registration date: **2015-03-11, 1393/12/20**

Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2015-03-11, 1393/12/20

Registrant information

Name

Saeid Yazdi-Ravandi

Name of organization / entity

Hamadan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 81 3827 1066

Email address

yazdiravandi@umsha.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research and Technology, Hamadan University of Medical Sciences

Expected recruitment start date

2015-06-22, 1394/04/01

Expected recruitment end date

2016-06-21, 1395/04/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of neurofeedback with pharmacotherapy on cognitive ability and executive function in patients with obsessive - compulsive disorder

Public title

The effect of neurofeedback with pharmacotherapy in treatment of patients with obsessive - compulsive disorder

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Diagnosis of obsessive-compulsive disorder based on the psychiatrist's interview According to DSM-5 criteria, Taking sertraline, Be at least 18 and up to 60 years, The ability to read and write, A minimum score of 16 on the Yale Brown Obsessive Compulsive Scale. Exclusion criteria: The people with acute and serious mental disorders such as bipolar disorder, schizophrenia, etc, People with other medical illnesses such as head injuries, Neurologic Diseases, drug allergies, A history of substance abuse, The types of dementia and cognitive disabilities.

Age

From **18 years** old to **60 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: **45**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Single blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Hamadan University of Medical Sciences

Street address

Vice chancellor for research and Technology,
Hamadan University of Medical Sciences, Shahid
Fahmideh Bulv, Hamadan

City

Hamadan

Postal code

6517838678

Approval date

2015-03-02, 1393/12/11

Ethics committee reference number

16/35/9/6369/پ

Health conditions studied

1

Description of health condition studied

obsessive - compulsive disorder

ICD-10 code

F42

ICD-10 code description

Obsessive-compulsive disorder

Primary outcomes

1

Description

Severity of symptoms of OCD

Timepoint

before and after the intervention

Method of measurement

Y_BOCS and CGI Scale

Secondary outcomes

1

Description

Cognitive ability and executive function

Timepoint

before and after the intervention

Method of measurement

Wisconsin, Stroop and Pasat tests

Intervention groups

1

Description

Group 2: In this group patients will receive placebo
Neurofeedback 2 times per week for 10 weeks and they
also will receive sertraline 20-40 mg per day for 16
weeks

Category

Other

2

Description

Group 3: In this group patients will receive sertraline 10
mg per day for 16 weeks.

Category

Treatment - Drugs

3

Description

Group 1: In this group patients will receive Neurofeedback 2 times per week For 10 weeks and they also will receive sertraline 20-40 mg per day for 16 weeks

Category

Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Farshchain psychiatry hospital

Full name of responsible person

Dr. Ali Ghaleiha

Street address

Farshchain psychiatry hospital, Dibaj st

City

Hamadan

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research and Technology,
Hamadan University of Medical Sciences

Full name of responsible person

Dr. Saeid Bashiryan

Street address

Vice chancellor for research and Technology,
Hamadan University of Medical Sciences, Fahmideh
Bulv

City

Hamadan

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice chancellor for research and Technology, Hamadan
University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Hamadan University of Medical Sciences

Full name of responsible person

Saeid Yazdi-Ravandi

Position

PhD student

Other areas of specialty/work

Street address

Research Center for Behavioral Disorder And
Substance Abuse. Farshchian Hospital, Hamadan

City

Hamadan

Postal code

6517838678

Phone

+98 81 3827 1066

Fax

Email

saeid_yazdiravandi@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Hamadan University of Medical Sciences

Full name of responsible person

Dr. Ali Ghaleiha

Position

Associate Professor

Other areas of specialty/work

Street address

Research Center for Behavioral Disorders and
Substance Abuse, Farshchaian Hospital, Hamadan

City

Hamadan

Postal code

6516848741

Phone

+81 38271066

Fax

Email

Alighaleiha@yahoo.co.uk

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Full name of responsible person

Position

Other areas of specialty/work

Street address

City

Postal code

6516848741

Phone

+98 81 3827 1066

Fax

Email

Saeid_yazdiravandi@yahoo.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty